Positive Results

 
News Articles for Positive Results top ^
Exelixis Inc. (NASDAQ:EXEL) today announced the positive results from coBRIM, the phase 3 pivotal trial conducted by Exelixis’ collaborator Genentech, a member of the Roche Group, evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma harboring a BRAF V600 mutation.
Sign-up for Exelixis Announces Positive Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafenib in Patients with BRAF V600 Mutation-Positive Advanced Melanoma investment picks
Strongly Positive Results, Presented at European Society for Medical Oncology (ESMO) 2014 Congress, Demonstrated Oncotype DX® Prostate Cancer Test was an Independent Predictor of Tumor Aggressiveness Study, Including 20% African-American Men, Confirmed Similar Predictive Outcomes Regardless of Race REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Positive Results from Latest Clinical Validation Study of Oncotype DX® as Predictor of Near- and Long-term Outcomes in Racially Diverse Group of Prostate Cancer Patients investment picks
2014/9/16
Achieved Primary 30 Day Endpoint Patients in CARENET Trial had significantly lower incidence of new ischemic lesions compared to historical control groups of non-mesh covered carotid stents BOSTON , Sept.
Sign-up for InspireMD Announces Positive Results from CGuard™ CARENET Trial with 0% MACE reported at 30 Days investment picks
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced positive results from the phase III study of triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) administered subcutaneously in patients with locally advanced or metastatic prostate cancer at the European Association of Urology (EAU) 14 th Central European Meeting in Cracow, Poland (10-12 October 2014). The primary objective of the study was to assess the efficacy and safety profile of the sustained-release triptorelin pamoate 11.25 mg (Decapeptyl ® 3 months) formulation when administered by the subcutaneous route in men with locally advanced or metastatic prostate cancer.
Sign-up for Ipsen Announces Positive Results from Phase III Clinical Study of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered by Subcutaneous Route to Prostate Cancer Patients investment picks
Dupilumab Demonstrated Improvement in Lung Function, Reductions of Severe Exacerbations TARRYTOWN, N.Y. and PARIS , Nov.
Sign-up for Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma investment picks
-- Primary endpoint was met for 50 mg twice daily dosing --
Sign-up for Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients investment picks
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced the initiation of a rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration for hydrocodone bitartrate extended-release tablets designed with Teva’s proprietary technology providing potential abuse-deterrent properties (CEP-33237) as allowed for fast track designated products.
Sign-up for Teva Announces Initiation of New Drug Application and Positive Results from Second Human Abuse Liability Study for CEP-33237 (Hydrocodone Bitartrate) Extended-Release Tablets investment picks
Phase 1 Clinical Trial Highlights: SANTA MONICA, Calif., Oct.
Sign-up for Kite Pharma Announces Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) Experience Positive Results After Receiving Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells investment picks
http://media.marketwire.com/attachments/201408/268735_TheravanceBiopharmaLogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155895&ProfileId=051205&sourceType=1 SOUTH SAN FRANCISCO, CA --
Sign-up for Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study of TD-6450, an NS5A Inhibitor to Treat Hepatitis C investment picks
2014/10/29
Trial meets primary endpoint with I.V. CR845 showing highly statistically significant reductions (p <0.0001) in scores for "drug liking," as well as "feeling high", "overall liking", and "take drug again" when compared to I.V. pentazocine, a Schedule IV opioid analgesic Results suggest potential for I.V. CR845 to be first Schedule V or non-scheduled peripheral opioid for acute pain Conference Call/Webcast at 9:00 a.m. ET today SHELTON, Conn., Oct.
Sign-up for Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845 investment picks
2014/11/19
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G026899-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/11/20/11G026899/Vivakor_logo-191968837290-787324512543-655670821004.jpg IRVINE, CA--(Marketwired - November 19, 2014) - Vivakor Inc. (PINKSHEETS: VIVK) announced GAAP based financial results for the quarter ended September 30, 2014.
Sign-up for Vivakor Surprises Again With Solid 3rd Quarter 2014 Financials and 6th Straight Quarter of Positive Results investment picks
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from a phase 2 trial assessing safety, efficacy and dose-response of three different once-daily oral SP-333 tablets (1.0, 3.0 and 6.0 mg) compared with placebo in 289 patients with opioid-induced constipation (OIC). Preliminary analysis of the data indicates SP-333 met the study’s primary endpoint and demonstrated statistically significant improvement in mean change from baseline in the number of spontaneous bowel movements (SBMs) during Week 4 of the treatment period.
Sign-up for Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation investment picks
2014/12/2
New and Updated Results Show 50% Response Rate in 14 Cardiac-Evaluable Patients New Data Show 43% Best Response Rate in 14 Renal-Evaluable Patients Cardiac and Renal Biomarker Responses of Single-Agent NEOD001-Treated Patients Compare Favorably with Historical Data in Patients with AL Amyloidosis NEOD001 Continues to be Safe and Well-Tolerated, with No Dose Limiting Toxicities Observed Excellent Pharmacokinetic Properties and No Immunogenicity Currently Enrolling Expansion Portion of Phase 1/2 Trial with New Data Expected to be Presented Annually at Appropriate Medical Conferences, Beginning in 2015 Prothena to Host Investor Conference Call and Webcast Today at 4:30 p.m. ET DUBLIN, Ireland, Dec.
Sign-up for Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis investment picks
LAS VEGAS , Dec.
Sign-up for Preclinical Xenograft Studies Show Positive Results For Amooranin investment picks
Results from First Clinical Study Using NGS-based Proprietary Liquid Biopsy Platform to Detect Presence of Breast Cancer Also Will Be Presented REDWOOD CITY, Calif.
Sign-up for Genomic Health Announces Oral Presentation of Positive Results from Second Large, Independent Clinical Validation Study of Oncotype DX® in DCIS Breast Cancer at 2014 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?docid=0969706001&sourceType=1 http://media3.marketwire.com/logos/20130529-r529a.jpg TORONTO, ONTARIO --
Sign-up for Rubicon Intersects 136.5 g/t Au Over 4.0 Metres as Infill Drilling at the Phoenix Gold Project Continues to Yield Positive Results investment picks
http://media.marketwire.com/attachments/201307/63937_Clipboard01.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1147785&ProfileId=051205&sourceType=1 LYON, FRANCE --
Sign-up for Flamel Technologies Announces Positive Results of First-in-Man Clinical Trial With LiquiTime(R) Ibuprofen investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Positive Results
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Portfolio X-Ray  |  Next: Possible Securities Law